Clinical Trials
279
Active:10
Completed:122
Trial Phases
5 Phases
Early Phase 1:5
Phase 1:84
Phase 2:118
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (256 trials with phase data)• Click on a phase to view related trials
Phase 2
118 (46.1%)Phase 1
84 (32.8%)Not Applicable
47 (18.4%)Early Phase 1
5 (2.0%)Phase 3
2 (0.8%)Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 32
- Registration Number
- NCT07008638
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
Allo HSCT for High Risk Hemoglobinopathies
Phase 2
Recruiting
- Conditions
- Graft FailureSickle Cell DiseaseHemoglobinopathies
- Interventions
- Radiation: Total Body IrradiationBiological: Cell Infusion
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 62
- Registration Number
- NCT06872333
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Phase 2
Not yet recruiting
- Conditions
- Follicular LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 65
- Registration Number
- NCT06792825
Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies
Not Applicable
Not yet recruiting
- Conditions
- Solid Tumor, AdultCytotoxicity
- Interventions
- Other: PlaceboBiological: Lactobacillus and Bifidobacterium
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 40
- Registration Number
- NCT06772090
Adenovirus (RGDCRAdCOX2F)
Phase 1
Recruiting
- Conditions
- Adenocarcinoma of Pancreas
- Interventions
- Biological: Replicative Adenovirus Vector (RGDCRAdCOX2F)
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 18
- Registration Number
- NCT06693986
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 56
- Next
News
No news found